These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 23387089)
1. [Preparation and characterization of irinotecan hydrochloride loaded PEO-PPO-PEO micelles and its mechanism of decreasing drug intestinal toxicity]. Zhang XX; Guo SY; Li FF; Gan Y Yao Xue Xue Bao; 2012 Nov; 47(11):1534-40. PubMed ID: 23387089 [TBL] [Abstract][Full Text] [Related]
2. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2). Guo S; Zhang X; Gan L; Zhu C; Gan Y J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031 [TBL] [Abstract][Full Text] [Related]
3. Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs. Zhang XX; Pan WS; Gan L; Zhu CL; Gan Y Acta Pharmacol Sin; 2008 Nov; 29(11):1391-8. PubMed ID: 18954535 [TBL] [Abstract][Full Text] [Related]
4. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895 [TBL] [Abstract][Full Text] [Related]
5. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments. Simonoska Crcarevska M; Geskovski N; Calis S; Dimchevska S; Kuzmanovska S; Petruševski G; Kajdžanoska M; Ugarkovic S; Goracinova K Eur J Pharm Sci; 2013 Apr; 49(1):65-80. PubMed ID: 23439240 [TBL] [Abstract][Full Text] [Related]
6. A fluorescence study of the loading and time stability of doxorubicin in sodium cholate/PEO-PPO-PEO triblock copolymer mixed micelles. Tasca E; Giudice AD; Galantini L; Schillén K; Giuliani AM; Giustini M J Colloid Interface Sci; 2019 Mar; 540():593-601. PubMed ID: 30677613 [TBL] [Abstract][Full Text] [Related]
7. PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions. Koliqi R; Dimchevska S; Geskovski N; Petruševski G; Chacorovska M; Pejova B; Hristov DR; Ugarkovic S; Goracinova K Curr Drug Deliv; 2016; 13(3):339-52. PubMed ID: 26728136 [TBL] [Abstract][Full Text] [Related]
8. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652 [TBL] [Abstract][Full Text] [Related]
13. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871 [TBL] [Abstract][Full Text] [Related]
14. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897 [TBL] [Abstract][Full Text] [Related]
15. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Watanabe M; Kawano K; Yokoyama M; Opanasopit P; Okano T; Maitani Y Int J Pharm; 2006 Feb; 308(1-2):183-9. PubMed ID: 16324807 [TBL] [Abstract][Full Text] [Related]
16. [Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats]. Takasuna K; Kasai Y; Kitano Y; Mori K; Kakihata K; Hirohashi M; Nomura M Nihon Yakurigaku Zasshi; 1995 Jun; 105(6):447-60. PubMed ID: 7557733 [TBL] [Abstract][Full Text] [Related]
17. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376 [TBL] [Abstract][Full Text] [Related]
19. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats. Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871 [TBL] [Abstract][Full Text] [Related]
20. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]